A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance
Communications Chemistry, 2022 Clinical efficacy of oxaliplatin is frequently limited by severe adverse effects and therapy resistance. Acquired insensitivity to oxaliplatin is, at least in part, associated with elevated levels of glutathione (GSH).
Philipp Fronik +9 more
semanticscholar +6 more sources
USF1-activated hsa_circ_0076691 induces oxaliplatin resistance via facilitating FGF9 expression in miR-589-3p-dependent manners [PDF]
Non-coding RNA ResearchChemotherapeutic efficacy in colorectal cancer (CRC) is significantly hindered by the development of drug resistance. Emerging evidence indicates that circular RNAs (circRNAs) play pivotal roles in various cancer-related biological processes. Nonetheless,
Lingyu Tang +3 more
doaj +2 more sources
Oxaliplatin-resistant colorectal cancer models for nanoparticle hyperthermia [PDF]
International Journal of Hyperthermia, 2021 Metastatic colorectal cancer (CRC) is complicated by chemotherapy-resistant cell populations. Oxaliplatin is used in heated intraperitoneal hyperthermic chemoperfusion (HIPEC) for treatment of disseminated CRC. Photothermal nanoparticles can provide focal heating to improve the response of CRC cells to oxaliplatin, by confining heating near individual ...
Bryce McCarthy +2 more
openaire +3 more sources
Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells [PDF]
, 2013 Colorectal cancer is the third leading cause of cancer-related mortality in the world-- the main cause of death from colorectal cancer is hepatic metastases, which can be treated with isolated hepatic perfusion (IHP).
A Jemal +52 more
core +15 more sources
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance [PDF]
Molecular Cancer Therapeutics, 2015 AbstractOxaliplatin was the first platinum drug with proven activity against colorectal tumors, becoming a standard in the management of this malignancy. It is also considered for the treatment of pancreatic and gastric cancers. However, a major reason for treatment failure still is the existence of tumor intrinsic or acquired resistance. Consequently,
Eva, Martinez-Balibrea +10 more
openaire +4 more sources
Translational Oncology, 2023 Oxaliplatin is a commonly used platinum drug for colorectal cancer (CRC). However, the treatment of CRC by oxaliplatin usually fails because of drug resistance, which results in a huge challenge in the therapy of CRC.
Qingling Hua +8 more
doaj +1 more source
Ferroptosis-related oxaliplatin resistance in multiple cancers: Potential roles and therapeutic Implications. [PDF]
HeliyonZhong S +4 more
europepmc +2 more sources
Pharmaceuticals, 2022 Aberrant expression of genes contributes to the chemoresistance of colorectal cancer (CRC) treatment. This study aimed to identify genes associated with the chemoresistance of oxaliplatin-based chemotherapy in CRC patients and to construct a signature ...
Yixin Yin +5 more
doaj +1 more source
LRRC8A promotes the initial development of oxaliplatin resistance in colon cancer cells
Heliyon, 2023 Leucine-rich repeat-containing 8 A (LRRC8A) is an essential component of the volume-regulated anion channel (VRAC), which plays a vital role in cell proliferation, migration, apoptosis, and drug resistance.
Haifeng Zhang +9 more
doaj +1 more source
WBSCR22 confers oxaliplatin resistance in human colorectal cancer [PDF]
Scientific Reports, 2017 AbstractHuman WBSCR22 gene is involved in tumor metastasis, cell growth and invasion, however, its role in chemosensitivity to antitumor agents remains unknown. In this study, we analyzed the TCGA cohort and found the expression of WBSCR22 was significantly elevated in human colorectal cancer (CRC) tissue. WBSCR22 could be served as an independent risk
Yan, Dongmei +6 more
openaire +2 more sources